Endurance training is feasible in severely disabled patients with progressive multiple sclerosis

Mult Scler. 2014 Apr;20(5):627-30. doi: 10.1177/1352458513505351. Epub 2013 Sep 20.

Abstract

This study tested whether upper-body endurance training (ET) is feasible and can be performed at sufficient intensity to induce cardiovascular adaptations in severely disabled patients with progressive multiple sclerosis (MS). Eleven progressive MS patients (6.5 ≤ EDSS ≤ 8.0) scheduled for a four-week inpatient rehabilitation program were randomized to a control group (CON, n = 5) that received standard individualized MS rehabilitation or an intervention group (EXE, n = 6) that in addition received 10 sessions of predominantly upper-body ET. One patient dropped out of the EXE group (drop-out rate: 1/6~17%) and no adverse events were recorded. The EXE group completed on average 9.3±0.8 sessions (~96.0±5%). During the ET sessions an average heart rate of 93.9±9.3beats*min(-1) were sustained corresponding to 91.6±6.8% of the maximal pre-intervention heart rate. In the EXE group a trend toward a time*group interaction was seen for VO2peak (p = 0.06). ET is feasible in severely disabled patients with progressive MS and it can probably be performed at sufficient intensity to induce cardiovascular adaptations.

Trial registration: ClinicalTrials.gov NCT01752660.

Keywords: Aerobic training; cardiovascular training; exercise; exercise therapy; upper body exercise.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptation, Physiological
  • Aged
  • Cardiovascular System / physiopathology
  • Denmark
  • Disability Evaluation
  • Exercise Therapy / methods*
  • Feasibility Studies
  • Female
  • Heart Rate
  • Humans
  • Male
  • Middle Aged
  • Multiple Sclerosis, Chronic Progressive / diagnosis
  • Multiple Sclerosis, Chronic Progressive / physiopathology
  • Multiple Sclerosis, Chronic Progressive / therapy*
  • Muscle Contraction
  • Muscle Strength*
  • Muscle, Skeletal / physiopathology*
  • Oxygen Consumption
  • Physical Endurance*
  • Severity of Illness Index
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome
  • Upper Extremity

Associated data

  • ClinicalTrials.gov/NCT01752660